FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease
Background and aim: Intestinal failure-associated liver disease (IFALD) is a clinical challenge. The pathophysiology is multifactorial and remains poorly understood. Disturbed recirculation of bile salts, e.g. due to loss of bile via an enterocutaneous fistula, is considered a major contributing factor. We hypothesize that impaired signaling via the bile salt receptor FXR underlies the development of IFALD. The aim of this study was to investigate whether activation of FXR improves liver homeostasis during chronic loss of bile in rats.
Methods: To study consequences of chronic loss of bile, rats underwent external biliary drainage (EBD) or sham surgery for seven days, and the prophylactic potential of the FXR agonist INT-747 was assessed.
Results: EBD for 7 days resulted in liver test abnormalities and histological liver damage. Expression of the intestinal FXR target gene Fgf15 was undetectable after EBD, and this was accompanied by an anticipated increase in hepatic Cyp7a1 expression, indicating increased bile salt synthesis. Treatment with INT-747 improved serum biochemistry, reduced loss of bile fluid in drained rats and prevented development of drainage-associated histological liver injury.
Conclusions: EBD results in extensive hepatobiliary injury and cholestasis. These data suggest that FXR activation might be a novel therapy in preventing liver dysfunction in patients with intestinal failure.
Relevance for patients: This study demonstrates that chronic loss of bile causes liver injury in rats. Abrogated recycling of bile salts impairing of enterohepatic bile salt/FXR signaling underlies these pathological changes, as administration of FXR agonist INT747 prevents biliary drainage-induced liver damage. Pharmacological activation of FXR might be a therapeutic strategy to treat disorders accompanied by a perturbed enterohepatic circulation such as intestinal failure-associated liver disease.
[1] Kelly D. Intestinal failure-associated liver disease: what do we know today? Gastroenterology. 2006; 130: 7.
[2] Gabe SM, Culkin A. Abnormal liver function tests in the parenteral nutrition fed patient. Frontline Gastroenterology. 2010; 1.
[3] Wiles A, Woodward JM. Recent advances in the management of intestinal failure-associated liver disease. Curr Opin Clin Nutr Metab Care. 2009; 12: 265-272.
[4] Visschers RG, Olde Damink SW, Schreurs M, Winkens B, Soeters PB, van Gemert WG. Development of hypertriglyceridemia in patients with enterocutaneous fistulas. Clin Nutr. 2009; 2: 313-317.
[5] Rinsema W, Gouma DJ, von Meyenfeldt MF, Soeters PB. Reinfusion of secretions from high-output proximal stomas or fistulas. Surg Gynecol Obstet. 1988; 167: 372-376.
[6] Wu Y, Ren J, Wang G, Zhou B, Ding C, Gu G, Chen J, Liu S, Li J. Fistuloclysis improves liver function and nutritional status in patients with high-output upper enteric fistula. Gastroenterol Res Pract. 2014: 941514.
[7] Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre. Clin Nutr. 2017; 36: 593-600.
[8] Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014; 11: 55-67.
[9] Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60: 463-472.
[10] Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology. 2008; 48: 1383-1386.
[11] Inagaki T, Choi M, Moschetta A, Peng L, Cummins C, McDonald J, Luo G, Jones S, Goodwin B, Richardson J, Gerard R, Repa J, Mangelsdorf D, Kliewer S. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell metabolism. 2005; 2: 217- 225.
[12] Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012; 56: 1034-1043.
[13] Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JR. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol. 2013; 304: G940-948.
[14] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005; 2: 217-225.
[15] Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012; 142: 355-65 e1-4.
[16] Kuipers F, Havinga R, Bosschieter H, Toorop GP, Hindriks FR, Vonk RJ. Enterohepatic circulation in the rat. Gastroenterology. 1985; 88: 403-411.
[17] de Haan J-J, Lubbers T, Hadfoune Mh, Luyer M, Dejong C, Buurman W, Greve J-WM. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Annals of surgery. 2008; 248: 842-848.
[18] Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994; 179: 269-277.
[19] Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015; 61: 161-170.
[20] Kunne C, Acco A, Hohenester S, Duijst S, de Waart DR, Zamanbin A, Oude Elferink RP. Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity. Hepatology. 2013; 57: 1509-1517.
[21] Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989; 30: 719-730.
[22] Lenicek M, Vecka M, Zizalova K, Vitek L. Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7alpha-hydroxy-4- cholesten-3-one, a surrogate marker of bile acid synthesis. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1033- 1034: 317-320.
[23] Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM. 6alpha-ethylchenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002; 45: 3569-3572.
[24] Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg. 2004; 239: 510-517.
[25] Bolder U, Ton-Nu H, Schteingart C, Frick E, Hofmann A. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology. 1997; 112: 214-225.
[26] Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen P, Elferink R. Impaired hepatocanalicular organic anion transport in endotoxemic rats. The American journal of physiology. 1995; 269: 34.
[27] Moseley R, Wang W, Takeda H, Lown K, Shick L, Ananthanarayanan M, Suchy F. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. The American journal of physiology. 1996; 271: 46.
[28] Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig Dis Sci. 1993; 38: 1291-1296.
[29] Kakar S, Batts KP, Poterucha JJ, Burgart LJ. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod Pathol. 2004; 17: 874-878.
[30] Uriarte I, Fernandez-Barrena M, Monte M, Latasa M, Chang H, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion A, Medina J, Marin J, Berasain C, Prieto J, Avila M. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut. 2013; 62: 899-910.
[31] Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990; 10: 2327-2334.
[32] Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48: 1632-1643.
[33] Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015; 61: 1066-1079.
[34] Hambruch E KO, Kremoser C. On the pharmacology of the Farnesoid X Receptor agonists: give me an "A”, like in "acid". Nucl Recept Res. 2016; 3: 101207.
[35] Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103: 3920-3925.
[36] Sheth P, Delos Santos N, Seth A, LaRusso NF, Rao RK. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G308-318.
[37] Anderson JM, Glade JL, Stevenson BR, Boyer JL, Mooseker MS. Hepatic immunohistochemical localization of the tight junction protein ZO-1 in rat models of cholestasis. Am J Pathol. 1989; 134: 1055-1062.
[38] Kawaguchi T, Sakisaka S, Sata M, Mori M, Tanikawa K. Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis. Hepatology. 1999; 29: 205-216.
[39] Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology. 2000; 31: 1285-1295.
[40] Denson L, Auld K, Schiek D, McClure M, Mangelsdorf D, Karpen S. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. The Journal of biological chemistry. 2000; 275: 8835-8843.
[41] Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK. Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem. 2003; 278: 27703-27711.
[42] Pereira-Fantini PM, Lapthorne S, Joyce SA, Dellios NL, Wilson G, Fouhy F, Thomas SL, Scurr M, Hill C, Gahan CG, Cotter PD, Fuller PJ, Hardikar W, Bines JE. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. J Hepatol. 2014; 61: 1115-1125.
[43] Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol. 2004; 7: 315-334.
[44] Naini B, Lassman C. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. Human pathology. 2012; 43: 826-833.
[45] Llop J, Virgili N, Moreno-Villares J, García-Peris P, Serrano T, Forga M, Solanich J, Pita A. Phytosterolemia in parenteral nutrition patients: implications for liver disease development. Nutrition (Burbank, Los Angeles County, Calif.). 2008; 24: 1145-1152.
[46] Jain A, Stoll B, Burrin D, Holst J, Moore D. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am J of Phy. Gastro and Liver Phys. 2012; 302: 24.